A novel drug regimen tested for the first time by researchers at Fred Hutch Cancer Center has shown great promise in ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Panelists discuss how therapy sequencing is approached for patients with chronic lymphocytic leukemia (CLL), with a focus on ...

Multiple steps are involved in the pathogenesis of chronic lymphocytic leukemia (CLL) and various factors are related to its development: cytogenetic aberrations, antigenic triggers activated by ...

and other adverse events—guide personalized treatment decisions in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) based on individual comorbidities and risk factors.

Background: Cholesterol metabolism significantly impacts leukemia pathophysiology, affecting tumor cell survival ... revealing thematic classifications within this area. The diagram displays 19 ...

Leukaemia is a type of blood cancer, which starts in blood-forming tissue, such as the bone marrow, and causes large ... maturity (acute or chronic) and cell type (lymphocytic or myeloid).

This leads to conditions such as anemia, increased susceptibility to infections, and impaired clotting. Approximately 5% to 10% of patients with CLL present with B-symptoms, which are associated with ...

Treatment for CLL continues to change. Doctors are using newer targeted cancer drugs. This means a stem cell transplant is now a less common treatment for CLL. You have a transplant using donor cells ...

During a Case-Based Roundtable® event, Catherine Coombs, MD, discussed the BRUIN trial and recent NCCN updates on chronic lymphocytic leukemia. Peers & Perspectives in Oncology: Please discuss the ...